6304-89-8Relevant articles and documents
Structure-Activity Study of Nitazoxanide Derivatives as Novel STAT3 Pathway Inhibitors
Lü, Zirui,Li, Xiaona,Li, Kebin,Wang, Cong,Du, Tingting,Huang, Wei,Ji, Ming,Li, Changhong,Xu, Fengrong,Xu, Ping,Niu, Yan
supporting information, p. 696 - 703 (2021/05/04)
We identified nitazoxanide (NTZ) as a moderate STAT3 pathway inhibitor through immunoblot analysis and a cell-based IL-6/JAK/STAT3 pathway activation assay. A series of thiazolide derivatives were designed and synthesized to further validate the thiazolide scaffold as STAT3 inhibitors. Eight out of 25 derivatives displayed potencies greater than that of NTZ, and their STAT3 pathway inhibitory activities were found to be significantly correlated with their antiproliferative activities in HeLa cells. Derivatives 15 and 24 were observed to be more potent than the positive control WP1066, which is under phase I clinical trials. Compared with NTZ, 15 also exhibited much improved in vivo pharmacokinetic parameters in rats and efficacies against proliferations in multiple cancer cell lines, indicating a broad-spectrum effect of these thiazolides as antitumor agents targeted on STAT3.
Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant
Chen, Guyue,Deng, Xianming,Deng, Zhou,Dong, Chao,Hu, Zhiyu,Li, Li,Li, Xiaoyang,Lian, Wenhua,Liu, Xueyan,Su, Jingyi,Wang, Zheng,Xu, Qingyan,Yang, Yanru,Yang, Zaiyou,Zhang, Baoding
, (2020/09/02)
The receptor tyrosine kinase rearranged during transfection (RET) plays pivotal roles in several cancers, including thyroid carcinoma and non-small cell lung cancer (NSCLC). Currently, there are several FDA-approved RET inhibitors, but their indication is limited to thyroid cancer, and none can overcome their gatekeeper mutants (V804L and V804M). Here, we report the discovery of 9x representing a new chemotype of potent and selective RET inhibitors, using a rational design strategy of type II kinase inhibitors. 9x exhibited both superior antiproliferative activities against NSCLC-related carcinogenic fusions KIF5B-RET and CCDC6-RET and gatekeeper mutant-transformed Ba/F3 cells, with the lowest GI50 of 9 nM, and substantial inhibitory activities against wild-type RET and RET mutant proteins, with the best IC50 of 4 nM. More importantly, 9x also showed nanomole potency against RET-positive NSCLC cells LC-2/ad, but not against a panel of RET-negative cancer cells, such as A549, H3122, A375 or parental Ba/F3 cells, demonstrating its selective ‘on-target’ effect. In mouse xenograft models, 9x repressed tumor growth driven by both wild type KIF5B-RET-Ba/F3 and gatekeeper mutant KIF5B-RET(V804M)-Ba/F3 cells in a dose-dependent manner. Together, these data establish that 9x provides a good starting point for the development of targeted therapeutics against RET-positive cancers, especially NSCLC.
Technological method for preparing m-aminophenol
-
Paragraph 0031; 0032; 0038-0044; 0066; 0067; 0090; 0091, (2018/04/01)
The invention relates to a technological method for preparing m-aminophenol, belongs to the technical field of chemical material preparation and solves the technical problem of limit caused by utilizing phenyl acetate as a preparation raw material. The technological method disclosed by the invention has the advantages of simpleness in operation, high product yield, reaction easy to control and thelike. The technological method is characterized by comprising the steps: preparing 3-carboxyphenyl phenyl acetate after preparing m-cresyl acetate and utilizing the prepared 3-carboxyphenyl phenyl acetate to prepare the m-aminophenol. The technological method comprises the steps: a, taking a C9H8O4 solvent, adding into an ethyl acetate solution, fully stirring until complete dissolution, dropwiseadding thionyl chloride into a system under the ice water bath condition, thermally insulating 1+/-0.5 hours, warming to 60 DEG C and refluxing; b, under the ice water bath condition, adding triethylamine and hydroxylamine hydrochloride into the system, thermally insulating for 2 hours and warming to a room temperature; c, spin drying the solvent on a rotary evaporator, then adding water and potassium carbonate, warming to 60 to 70 DEG C and hydrolyzing; d, utilizing ethyl acetate to extract the solution, utilizing a thin-layer chromatography to determine whether extraction is complete and obtaining the finished product of the m-aminophenol after the extraction is finished.